Download PDF
Klinische Neurophysiologie 2003; 34(3): 119-126
DOI: 10.1055/s-2003-42250
Übersicht
© Georg Thieme Verlag Stuttgart · New York

Multifokale motorische Neuropathie: Klinische und elektrophysiologische Charakteristika

Multifocal Motor Neuropathy: Clinical and Electrophysiological FindingsA.  Jaspert1 , H.  Grehl2
  • 1Klinik für Neurologie und Klinische Neurophysiologie, Alfried Krupp Krankenhaus, Essen
  • 2Neurologische Klinik, Evangelisches und Johanniter-Klinikum Duisburg
Further Information

Publication History

Publication Date:
18 September 2003 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Die multifokale motorische Neuropathie (MMN) ist eine behandelbare, vermutlich immunvermittelte Neuropathie. Die klinische Symptomatik ist durch asymmetrische, rein motorische Defizite charakterisiert, die dem Verteilungsmuster peripherer Nerven entsprechen und vorwiegend distale Abschnitte an den oberen Extremitäten betreffen. Die typischen elektrophysiologischen Befunde der MMN sind multifokale, häufig persistierende Leitungsblöcke, die die Abgrenzung der MMN von den nichtbehandelbaren Motoneuronerkrankungen erlauben. Da die Demyelinisierung bei der MMN nicht so ausgedehnt ist wie bei der chronisch-entzündlichen demyelinisierenden Polyneuropathie (CIDP), sind die Nervenleitgeschwindigkeiten oft normal. Um die Nachweismöglichkeit eines Leitungsblockes zu verbessern, sollten mittels spezieller elektrophysiologischer Stimulationstechniken proximale Nervenabschnitte mituntersucht werden. Antikörpertiter gegen GM1-Ganglioside können bei der MMN erhöht sein, reichen aber zur Diagnosesicherung nicht aus. Hoch dosierte intravenöse Immunglobuline (ivIg) und Zyklophosphamid sind die beiden einzigen gesicherten effektiven Therapieverfahren der MMN. IvIg sind aufgrund ihres günstigen Nebenwirkungsprofils die Therapie der ersten Wahl. Kortikosteroide und Plasmapherese können die neurologischen Symptome verschlechtern. Die schnelle Besserung nach einer Immunglobulintherapie könnte durch die Neutralisierung funktionell blockierender Antikörper bedingt sein. Immunglobuline sind auch im Langzeitverlauf effektiv. Bei einigen Patienten kann jedoch die Erkrankung trotz regelmäßiger Immunglobulinbehandlungen fortschreiten. Da eine Immunglobulinlangzeittherapie teuer ist, kann sie auch in Kombination mit Zyklophosphamid durchgeführt werden, um Immunglobuline einzusparen.

Abstract

Multifocal motor neuropathy (MMN) is a treatable, probably immune-mediated neuropathy. Typical clinical symptoms are asymmetrical pure motor deficits in a peripheral nerve distribution, predominantly affecting distal parts of upper limbs. The characteristic electrophysiological findings of MMN are multifocal and often persistent conduction blocks that can be differentiated from untreatable motor neuron disease. Since demyelination in MMN is not as widespread as in chronic inflammatory demyelinating polyneuropathy (CIDP), nerve conduction velocities are often normal. To improve the diagnosis of conduction blocks, electrophysiological studies should include proximal nerve segments using special stimulation techniques. Antibody titres against GM1 gangliosides may be elevated in MMN, but are not sufficient for diagnostic values. High dose intravenous immunoglobulins (IVIG) and cyclophosphamide are the only effective therapies in MMN, IVIG being the treatment of choice because of its less serious side effects. Corticosteroids and plasma exchange therapy may aggravate neurological deficits. Rapid improvement after IVIG application may be caused by neutralisation of functional blocking antibodies. IVIG is also effective in the long-term course. In some patients, however, disease progression may be observed despite of regular IVIG treatment. As long-lasting IVIG treatment is expensive, combination with cyclophosphamide may be performed to reduce the IVIG dosage. Application of further immunomodulatory drugs in MMN should be investigated in the future.

Key words

Multifocal motor neuropathy - MMM - conduction block - anti-GM1 - antibodies - immunoglobulin therapy - IVIG

Literatur

  • 1 Lewis R A, Sumner A J, Brown M J, Asbury A K. Multifocal demyelinating neuropathy with persistent conduction block.  Neurology. 1982;  32 958-964
    CrossrefPubMedGoogle Scholar
  • 2 Berg-Vos R M Van den, Berg L H Van den, Franssen H, Vermeulen M, Witkamp T D, Jansen G H, Es H W van, Kerkhoff H, Wokke J HJ. Multifocal inflammatory demyelinating neuropathy: A distinct clinical entity?.  Neurology. 2000;  54 26-32
    CrossrefPubMedGoogle Scholar
  • 3 Biessels G J, Franssen H, Berg L H Van den, Gibson A, Kappelle L J, Venables G S, Wokke J HJ. Multifocal motor neuropathy.  J Neurol. 1997;  244 143-152
    PubMedGoogle Scholar
  • 4 Chaudhry V, Corse A, Cornblath D, Kuncl R, Freimer M, Griffin J. Multifocal Motor Neuropathy: Electrodiagnostic Features.  Muscle Nerve. 1994;  17 198-205
    PubMedGoogle Scholar
  • 5 Jaspert A, Claus D, Grehl H, Neundörfer B. Multifocal motor neuropathy: clinical and electrophysiological findings.  J Neurol. 1996;  243 684-692
    CrossrefPubMedGoogle Scholar
  • 6 Leger J M. Multifocal motor neuropathy and chronic inflammatory demyelinating polyradiculoneuropathy.  Curr Opin Neurol. 1995;  8 359-363
    PubMedGoogle Scholar
  • 7 Lange D J, Trojaborg W, Latov N, Hays A P, Younger D S, Uncini A, Blake D M, Hirano M, Burns S M, Lovelace R E, Rowland L P. Multifocal motor neuropathy with conduction block: Is it a distinct clinical entity?.  Neurology. 1992;  42 497-505
    PubMedGoogle Scholar
  • 8 Taylor B V, Wright R A, Harper C M, Dyck P J. Natural history of 46 patients with multifocal motor neuropathy with conduction block.  Muscle Nerve. 2000;  23 900-908
    CrossrefPubMedGoogle Scholar
  • 9 Nobile-Orazio E. Multifocal motor neuropathy.  J Neurol Neurosurg Psychiatry. 1996;  60 599-603
    PubMedGoogle Scholar
  • 10 O'Leary C P, Mann A C, Lough J, Willison H J. Muscle hypertrophy in multifocal motor neuropathy is associated with continuous motor unit activity.  Muscle Nerve. 1997;  20 479-485
    PubMedGoogle Scholar
  • 11 Cornblath D R, Sumner A J, Daube J, Gilliat R W, Brown W F, Parry G J, Albers J W, Miller R G, Petajan J. Conduction block in clinical practice.  Muscle Nerve. 1991;  14 869-871
    PubMedGoogle Scholar
  • 12 Cappellari A, Nobile-Orazio E, Meucci N, Levi-Minzi G, Scarlato G, Barbieri S. Criteria for early detection of conduction block in multifocal motor neuropathy (MMN): a study based on control populations and follow-up of MMN patients.  J Neurol. 1997;  244 625-630
    PubMedGoogle Scholar
  • 13 Olney R K. Consensus criteria for the diagnosis of partial conduction block.  Muscle & Nerve. 1999;  22, Suppl 8 225-229
    PubMedGoogle Scholar
  • 14 Katz J S, Wolfe G I, Bryan W W, Jackson C E, Amato A A, Barohn R J. Electrophysiologic findings in multifocal motor neuropathy.  Neurology. 1997;  48 700-707
    CrossrefPubMedGoogle Scholar
  • 15 Berg-Vos R M Van den, Franssen H, Wokke J HJ, Es H W van, Berg L H Van den. Multifocal Motor Neuropathy: Diagnostic Criteria that Predict the Response to Immunoglobulin Treatment.  Ann Neurol. 2000;  48 919-926
    CrossrefPubMedGoogle Scholar
  • 16 Abu-Shakra S R, Cornblath D R, Avila O L, Chaudhry V, Freimer M, Glass J D, Reim J W, Ronnett G V. Conduction block in diabetic neuropathy.  Muscle Nerve. 1991;  14 858-862
    PubMedGoogle Scholar
  • 17 Rhee E K, England J D, Sumner A J. A computer simulation of conduction block: effects produced by actual block versus interphase cancellation.  Ann Neurol. 1990;  28 146-156
    CrossrefPubMedGoogle Scholar
  • 18 Franssen H, Wieneke G H, Wokke J HJ. The influence of temperature on conduction block.  Muscle Nerve. 1999;  22 166-173
    PubMedGoogle Scholar
  • 19 Rasminsky M. The effects of temperature on conduction block in demyelinating nerve fibers.  Arch Neurol. 1973;  28 287-292
    CrossrefPubMedGoogle Scholar
  • 20 Kaji R, Bostock H, Kohara N, Murase N, Kimura J, Shibasaki H. Activity-dependent conduction block in multifocal motor neuropathy.  Brain. 2000;  123 1602-1611
    CrossrefPubMedGoogle Scholar
  • 21 Cappelen-Smith C, Kuwabara S, Lin C S-Y, Mogyoros I, Burke D. Activity-Dependent Hyperpolarization and Conduction Block in Chronic Inflammatory Demyelinating Polyneuropathy.  Ann Neurol. 2000;  48 826-832
    CrossrefPubMedGoogle Scholar
  • 22 Jaspert A, Claus D, Grehl H, Kerling F, Neundörfer B. Wertigkeit der proximalen Leitungsblockuntersuchung in der Diagnostik entzündlicher Neuropathien.  Nervenarzt. 1995;  66 445-454
    PubMedGoogle Scholar
  • 23 Mills K R, Murray N MF. Electrical stimulation over the human vertebral column: Which neural elements are excited?.  Electroenceph clin Neurophysiol. 1986;  63 582-589
    CrossrefPubMedGoogle Scholar
  • 24 Claus D. Conduction studies in proximal nerves.  Schweizer Archiv für Neurologie und Psychiatrie. 1991;  142 531
    PubMedGoogle Scholar
  • 25 Azulay J-P, Rihet R, Pouget J, Cador F, Blin O, Boucraut J, Serratrice G. Long-term follow-up of multifocal motor neuropathy with conduction block under treatment.  J Neurol Neurosurg Psychiatry. 1997;  62 391-394
    PubMedGoogle Scholar
  • 26 Bouche P, Moulonguet A, Ben Younes-Chennoufi A, Adams D, Baumann N, Meininger V, Léger J-M, Said G. Multifocal motor neuropathy with conduction block: a study of 24 patients.  J Neurol Neurosurg Psychiatry. 1995;  59 38-44
    CrossrefPubMedGoogle Scholar
  • 27 Elliott J L, Pestronk A. Progression of multifocal motor neuropathy during apparently successful treatment with human immunoglobulin.  Neurology. 1994;  44 967-968
    PubMedGoogle Scholar
  • 28 Kolimas R J, Harati Y. Multifocal motor neuropathy: value of electrophysiologic studies and motor nerve biopsy.  Muscle Nerve. 1990;  13 868
    PubMedGoogle Scholar
  • 29 Krarup C, Stewart J D, Sumner A J, Pestronk A, Lipton S A. A syndrome of asymmetric limb weakness with motor conduction block.  Neurology. 1990;  40 118-127
    PubMedGoogle Scholar
  • 30 Report from an Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force . Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP).  Neurology. 1991;  41 617-618
    PubMedGoogle Scholar
  • 31 Pestronk A, Choksi R. Multifocal motor neuropathy. Serum IgM anti-GM1 ganglioside antibodies in most patients detected using covalent linkage of GM1 to ELISA plates.  Neurology. 1997;  49 1289-1292
    PubMedGoogle Scholar
  • 32 Santoro M, Uncini A, Corbo M. Experimental conduction block induced by serum from a patient with anti-GM1 antibodies.  Ann Neurol. 1992;  31 385-390
    CrossrefPubMedGoogle Scholar
  • 33 Benatar M, Willison H J, Vincent A. Immune-mediated peripheral neuropathies and voltage-gated sodium channels.  Muscle Nerve. 1999;  22 108-110
    PubMedGoogle Scholar
  • 34 Wurz A, Brinkmeier H, Wollinsky K H, Mehrkens H H, Kornhuber H H, Rudel R. Cerebrospinal fluid and serum from patients with inflammatory polyradiculoneuropathy have opposite effects on sodium channels.  Muscle Nerve. 1995;  18 772-781
    PubMedGoogle Scholar
  • 35 Takigawa T, Yasuda H, Kikkawa R, Shigeta Y, Saida T, Kitasato H. Antibodies against GM1 ganglioside affect K+ and Na+ currents in isolated rat myelinated nerve fibers.  Ann Neurol. 1995;  37 436-442
    CrossrefPubMedGoogle Scholar
  • 36 Hirota N, Kaji R, Bostock H, Shindo K, Kawasaki T, Kotaro M, Oka N, Kohara N, Saida T, Kimura J. The physiological effect of anti-GM1 antibodies on saltatory conduction and transmembrane currents in single motor axons.  Brain. 1997;  120 2159-2169
    CrossrefPubMedGoogle Scholar
  • 37 Weber F, Rüdel R, Aulkemeyer P, Brinkmeier H. Anti-GM1 antibodies can block neuronal voltage-gated sodium channels.  Muscle Nerve. 2000;  23 1414-1420
    PubMedGoogle Scholar
  • 38 Dalakas M C. Intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: present status and practical therapeutic guidelines.  Muscle Nerve. 1999;  22 1479-1497
    CrossrefPubMedGoogle Scholar
  • 39 Donaghy M, Mills K R, Boniface S J, Simmons J, Wright I, Gregson N, Jacobs J. Pure motor demyelinating neuropathy: deterioration after steroid treatment and improvement with intravenous immunoglobulin.  J Neurol Neurosurg Psychiatry. 1994;  57 778-783
    PubMedGoogle Scholar
  • 40 Claus D, Specht S, Zieschang M. Plasmapheresis in multifocal motor neuropathy: a case report.  J Neurol Neurosurg Psychiatry. 2000;  68 533-535
    CrossrefPubMedGoogle Scholar
  • 41 Carpo M, Cappellari A, Mora G, Pedotti R, Barbieri S, Scarlato G, Nobile-Orazio E. Deterioration of multifocal motor neuropathy after plasma exchange.  Neurology. 1998;  50 1480-1482
    CrossrefPubMedGoogle Scholar
  • 42 Feldman E L, Bromberg M B, Albers J W, Pestronk A. Immunosuppressive Treatment in Multifocal Motor Neuropathy.  Ann Neurol. 1991;  30 397-401
    CrossrefPubMedGoogle Scholar
  • 43 Azulay J-P, Blin O, Pouget J, Boucraut J, Billé-Turc F, Carles G, Serratrice G. Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: A double-blind, placebo-controlled study.  Neurology. 1994;  44 429-432
    PubMedGoogle Scholar
  • 44 Chaudhry V, Corse A, Cornblath D, Kuncl R, Drachman D, Freimer M, Miller R, Griffin J. Multifocal motor neuropathy: Response to human immune globulin.  Ann Neurol. 1993;  33 237-242
    CrossrefPubMedGoogle Scholar
  • 45 Grehl H, Jaspert A, Claus D, Neundörfer B. Long-term therapy with high-dose intravenous immunoglobulins (IVIG) in inflammatory neuropathies.  European Journal of Neurology. 1997;  4 266-273
    PubMedGoogle Scholar
  • 46 Léger J M, Younes-Chennoufi A B, Chassande B, Davila G, Bouche P, Baumann N, Brunet P. Human immunoglobulin treatment of multifocal motor neuropathy and polyneuropathy associated with monoclonal gammopathy.  J Neurol Neurosurg Psychiatry. 1994;  57, Suppl 46-49
    PubMedGoogle Scholar
  • 47 Nobile-Orazio E, Meucci N, Barbieri S, Carpo M, Scarlato G. High dose intravenous immunoglobulin therapy in multifocal motor neuropathy.  Neurology. 1993;  43 537-544
    PubMedGoogle Scholar
  • 48 Berg L H Van den, Kerkhoff H, Oey P L, Franssen H, Mollee I, Vermeulen M, Jennekens F GI, Wokke J HJ. Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study.  J Neurol Neurosurg Psychiatry. 1995;  59 248-252
    CrossrefPubMedGoogle Scholar
  • 49 Berg L H Van den, Franssen H, Oey P L, Wokke J HJ. The effect of intravenous immunoglobulin treatment in patients with multifocal motor neuropathy or lower motor neuron disease.  J Neurol. 1995;  242, Suppl 2 149
    PubMedGoogle Scholar
  • 50 Berg L H Van den, Franssen H, Wokke J H. Improvement of multifocal motor neuropathy during long-term weekly treatment with human immunoglobulin.  Neurology. 1995;  45 987-988
    PubMedGoogle Scholar
  • 51 Berg L H Van den, Franssen H, Wokke J HJ. The long-term effect of intravenous immunoglobulin treatment in multifocal motor neuropathy.  Brain. 1998;  121 421-428
    CrossrefPubMedGoogle Scholar
  • 52 Doorn P A van, Brand A, Strengers P F, Meulstee J, Vermeulen M. High-dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled, crossover study (see comments).  Neurology. 1990;  40 209-212
    PubMedGoogle Scholar
  • 53 Federico P, Zochodne D W, Hahn A F, Brown W F, Feasby T E. Multifocal motor neuropathy improved by IVIg: randomized, double-blind, placebo-controlled study.  Neurology. 2000;  55 1256-1262
    CrossrefPubMedGoogle Scholar
  • 54 Léger J-M, Chassande B, Musset L, Meininger V, Bouche P, Baumann N. Intravenous immunoglobulin therapy in multifocal motor neuropathy. A double-blind, placebo-controlled study.  Brain. 2001;  124 145-153
    CrossrefPubMedGoogle Scholar
  • 55 Cabre P, Smadja D, Odry L, Donikian J C, Vernant J C. Acute kidney failure following intravenous administration of high doses of immunoglobulins (letter).  Presse Med. 1994;  23 142
    PubMedGoogle Scholar
  • 56 Silbert P L, Knezevic W V, Bridge D T. Cerebral infarction complicating intravenous immunoglobulin therapy for polyneuritis cranialis.  Neurology. 1992;  42 257-258
    PubMedGoogle Scholar
  • 57 Bertorini T E, Nance A M, Horner L H, Greene W, Gelfand M S, Jaster J H. Complications of intravenous gammaglobulin in neuromuscular and other diseases.  Muscle Nerve. 1996;  19 388-391
    PubMedGoogle Scholar
  • 58 Berg-Vos R M Van den, Franssen H, Visser J, Visser M de, Haan R J de, Wokke J HJ, Berg L H Van den. Disease severity in multifocal motor neuropathy and its association with the response to immunoglobulin treatment.  J Neurol. 2002;  249 330-336
    PubMedGoogle Scholar
  • 59 Meucci N, Cappellari A, Barbieri S, Scarlato G, Nobile-Orazio E. Long-term effect of intravenous immunoglobulins and oral cyclophosphamide in multifocal motor neuropathy.  J Neurol Neurosurg Psychiatry. 1997;  63 765-769
    CrossrefPubMedGoogle Scholar
  • 60 Martina I S, Doorn P A van, Schmitz P I, Meulstee J, Meché F GA van der. Chronic motor neuropathies: response to interferon-beta 1a after failure of conventional therapies.  J Neurol Neurosurg Psychiatry. 1999;  66 197-201
    PubMedGoogle Scholar
  • 61 Levine T D, Pestronk A. IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using Rituximab.  Neurology. 1999;  52 1701-1704
    PubMedGoogle Scholar
  • 62 Scheglmann K, Rentz E. Treatment of chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy with high dose intravenous immunoglobulin with IgM, IgA in addition to IgG.  J Neurol. 2000;  247, Suppl 3 S III/64
    PubMedGoogle Scholar
  • 63 Ellis C M, Leary S, Payan J, Shaw C, Hu M, O'Brien M, Leigh P N. Use of human intravenous immunoglobulin in lower motor neuron syndromes.  J Neurol Neurosurg Psychiatry. 1999;  67 15-19
    PubMedGoogle Scholar
  • 64 Pestronk A, Chaudhry V, Feldman E L, Griffin J W, Cornblath D R, Denys E H, Glasberg M, Kuncl R W, Olney R K, Yee W C. Lower motor neuron syndromes defined by patterns of weakness, nerve conduction abnormalities, and high titers of antiglycolipid antibodies.  Ann Neurol. 1990;  27 316-326
    CrossrefPubMedGoogle Scholar

PD Dr. Andrea Jaspert

Klinik für Neurologie und Klinische Neurophysiologie · Alfried Krupp Krankenhaus

Alfried-Krupp-Straße 21

45117 Essen-Rüttenscheid